Research graph
References from CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Cilta-cel or standard care in lenalidomide-refractory multiple myeloma
10.1056/nejmoa2303379 · 2023 · External reference
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(25)00653-9 · 2026 · External reference
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
10.1016/s2352-3026(24)00320-x · 2025 · External reference
Teclistamab plus daratumumab in relapsed or refractory multiple myeloma
10.1056/nejmoa2514663 · 2026 · External reference
10.1182/bloodadvances.2026020073 · 2026 · Admitted local publication
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
10.1038/s41408-025-01343-4 · 2025 · External reference
Teclistamab, daratumumab, and pomalidomide in patients with relapsed/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm-2 studies
10.1182/blood-2024-200181 · 2024 · External reference
Unresolved reference
External reference
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
10.1016/s2352-3026(24)00005-x · 2024 · External reference
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
10.1038/s41408-024-01129-0 · 2024 · External reference
Mitigating time toxicity in lymphoma and multiple myeloma
10.1080/10428194.2024.2352086 · 2024 · External reference
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
10.1038/s41408-024-01043-5 · 2024 · External reference
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
10.1182/bloodadvances.2025016490 · 2025 · External reference
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
10.1182/blood.2023023616 · 2024 · External reference
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
10.1038/s41408-025-01314-9 · 2025 · External reference
10.1182/bloodadvances.2023012066
10.1182/bloodadvances.2023012066 · 2024 · External reference
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
10.1182/blood.2022015526 · 2023 · External reference
Early CD4+ T-cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy
10.1172/jci192927 · 2025 · External reference
T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma
10.1158/1078-0432.ccr-23-3333 · 2024 · External reference
International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
10.1038/s41375-024-02482-6 · 2025 · External reference
Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma
10.1200/jco-25-00760 · 2025 · External reference
